Two DelMar Pharmaceuticals Inc. executives recently accepted requests to join the National Brain Tumor Society's (NBTS) Research Roundtable, attending its premiere meeting in Washington, D.C. to consider ways research can improve clinical trials for regulatory approval.
CEO Jeffrey Bacha and Chief Scientific Officer Dennis Brown participated alongside peers in the neuro-oncology field and representatives from the U.S. Food and Drug Administration to brainstorm pathways for improved efficiency in future research efforts at the gathering, titled "Streamlining Clinical Trials to Accelerate Brain Tumor Drug Development."
"Dr. Brown and I are very enthusiastic about the potential of the NBTS Research Roundtable to have a significant impact in the development of new brain tumor treatments," Bacha said. “It is a privilege to work alongside distinguished researchers, colleagues from the National Brain Tumor Society, and the [National Cancer Institute] and FDA toward a common goal of bringing better treatments and cures to patients and families battling and surviving brain cancer."
Bacha also expressed appreciation for DelMar’s opportunity to forge bonds with others in the field, noting that partnerships will be of value as the company pursues important clinical trials for VAL-083, its lead product candidate.
DelMar Pharmaceuticals is based in Vancouver, British Columbia.
Alerts Sign-up